Iris
← Keeping up with Gene Editing - Monthly Roundups by Iris
October 2026 roundupPeriod scanned: 2 October – 1 November 20262 min listen

First-in-human DMD editing trial reports dystrophin signal and fatal toxicity

Audio briefing

2 min

In this report
October's only retained development pairs an early molecular signal in first-in-human DMD editing with a serious systemic safety limit. The result leaves delivery and dose selection unresolved rather than establishing clinical efficacy.
  1. The first-in-human systemic AAV9 program produced early molecular evidence of dystrophin restoration.
  2. The therapy achieved targeted genome editing in participants, extending in vivo editing into a clinical DMD setting.
  3. A dose of 1.0 × 1014 vg/kg was associated with a fatal adverse event involving complement activation and systemic cytokine response.
Clinical delivery and safety

DMD trial reports dystrophin signal and fatal toxicity

General
The first-in-human systemic AAV9 program produced early molecular evidence of dystrophin restoration, but dosing at 1.0 × 1014 vg/kg was associated with a fatal serious adverse event. The signal is therefore paired with evidence of a narrow therapeutic window for systemic AAV genome editing.
  • The single-vector therapy achieved targeted genome editing in participants; humanized DMD mice also showed improved muscle function.
  • The fatal event featured marked complement activation and a systemic cytokine response, identifying immune toxicity as the immediate development constraint.
The study tests whether systemic AAV delivery can carry genome editing into DMD muscle without unacceptable immune toxicity.
How Iris covered your topics this month
Every topic you track was searched over the last month.
TopicSources foundIn this briefing
General221 story
Appendix: 22 sources relevant to you, from 37 scanned
General · 21
Custom Gene-Editing Therapies for Rare Diseases Could ... · medicaldaily.com · 2026-10-30News
SmartPE enables efficient prime editing in dicot crops | Nature Plants · nature.com · 2026-10-28Research
News: CRISPR Trials Global Overview Q2 2026 from CMN Intelligence: 300+ Gene Editing Trials in the World's Only Manually Curated Global Database - CRISPR Medicine · crisprmedicinenews.com · 2026-10-27News
In vivo genome-editing therapy for Duchenne muscular dystrophy: Preclinical studies and first-in-human trial: Cell · cell.com · 2026-10-26Research
CRISPR gene editing: from one patient to a platform | Nature Research Custom · nature.com · 2026-10-25News
Base editing-mediated exon-specific knockout of glutamine synthetase generates a high-productivity CHO cell line for antibody manufacturing | Bioresources and Bioprocessing | Springer Nature Link · link.springer.com · 2026-10-23Research
A first for CRISPR: powerful prime editing alters DNA directly in the human body | Nature · nature.com · 2026-10-22 · 2 outletsNews
New CRISPR Delivery Platform Reactivates Silenced Angelman Syndrome Gene Across the Brain - ASHG · ashg.org · 2026-10-21News
Engineered human Argonaute 2 for targeted C-to-U RNA base editing | Nature Biotechnology · nature.com · 2026-10-20Research
Translating base editors: a decade of progress from the bench to the clinic | Nature Reviews Drug Discovery · nature.com · 2026-10-16Research
In Vivo Gene Editing: What the Clinical Data Now Shows · lifesciencedaily.news · 2026-10-16News
In-vivo CRISPR/Base-Editing “One-Shot” Therapies Targeting PCSK9 | Current Atherosclerosis Reports | Springer Nature Link · link.springer.com · 2026-10-15Research
Breaking barriers in brain gene therapy | Drug Discovery News · drugdiscoverynews.com · 2026-10-14News
PrimeStack editors enable efficient and site-specific integration of large multigene cargos in plants | PLOS Biology · journals.plos.org · 2026-10-13Research
News: CMN Webinar - Expert Discussion: Rethinking Cell & Gene Therapy Safety - CRISPR Medicine · crisprmedicinenews.com · 2026-10-12News
Genome editing for hereditary angioedema: A landmark trial and important unanswered questions: Med · cell.com · 2026-10-09Research
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 | CRISPR Therapeutics · ir.crisprtx.com · 2026-10-08News
Repurposing base editors for targeted knockin and simultaneous multiplex knockouts to generate allo-CAR T cells with minimal translocations - ScienceDirect · sciencedirect.com · 2026-10-07Research
New technique holds promise for improved gene editing | Cornell Chronicle · news.cornell.edu · 2026-10-07Announcement
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes | ACS Nano | ACS Publications · pubs.acs.org · 2026-10-06Research
Nanoparticles designed for longer RNA delivered gene editors to three mouse organs | NOWPOSSIBLE · nowpossible.eu · 2026-10-05News
15 more scanned and set aside
AP News in Brief at 12:04 a.m. EST | kvue.com · kvue.com · 2026-11-01News
AP News in Brief at 12:04 a.m. EDT | 10tv.com · 10tv.com · 2026-11-01News
U.S. News - WSJ.com · wsj.com · 2026-11-01News
Approved Cellular and Gene Therapy Products · fda.gov · 2026-10-31Official
CRISPR clinical trials: gene editing explained for patients … · clinicaltrials.eu · 2026-10-30News
NBC News - Breaking Headlines and Video Reports on World, U.… · nbcnews.com · 2026-10-29News
News Releases | Washington State · atg.wa.gov · 2026-10-29Official
News | Today's latest from Al Jazeera · aljazeera.com · 2026-10-27News
Associated Press News: Breaking News · apnews.com · 2026-10-21News
News and current affairs from Germany and around the world · dw.com · 2026-10-19News
Why In Vivo Innovation Regulatory Convergence Will Help Shap… · cellandgene.com · 2026-10-19News
Company: Novo Nordisk · crisprmedicinenews.com · 2026-10-19News
Manufacturing Viral Vectors for Gene and Cell Therapies · ctgct.si · 2026-10-13News
Genome Editing Market Size, Trends & Growth Analysis ... · fortunebusinessinsights.com · 2026-10-12Low signal
CRISPR Gene Therapy for Skin: How Gene Editing Could Change … · boldpurity.com · 2026-10-05News
Tell Iris what to cover more, less, or differently. It shapes your next briefing.
This briefing was generated by Iris Briefings.
Iris uses artificial intelligence to synthesise recent developments in your field. It can make mistakes, so please verify anything critical against the linked primary sources before acting on it. Thank you for supporting Iris.

Want this for your field?

Iris builds a briefing agent around your own profile: your field, your focus areas, your context. Delivered on your schedule.

Get your own briefing

Iris is a tool that uses AI to find publicly available information and extract the insights that matter for you. Iris Briefings have taken precautions to ensure our systems are robust but these are not infallible. Nothing in your briefings should be taken for medical, legal or professional advice and Iris cannot take responsibility for your decisions. We encourage you to do your own due diligence on the primary sources that Iris references for critical decisions.